Annual report pursuant to Section 13 and 15(d)

Equity Investment (Details Narrative)

v3.24.0.1
Equity Investment (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Aug. 24, 2022
Schedule of Equity Method Investments [Line Items]      
Unrealized gain securities $ 3,883,000    
Principal amount - convertible note 1,000,000    
Accrued interest - convertible note 86,000    
Unrealized gain on conversion - convertible note $ 271,000  
Additional Comprehensive loss (1,443,000) (2,328,000)  
Additional net loss $ (1,457,000) (2,326,000)  
Iliad [Member]      
Schedule of Equity Method Investments [Line Items]      
Ownership percentage fully diluted 5.40%    
Equity investment net loss $ 2,003,000 1,639,000  
Book value of investment 5,515,000    
Additional Comprehensive loss   621,000  
Additional net loss $ 42,000    
Iliad [Member] | Class C Units [Member]      
Schedule of Equity Method Investments [Line Items]      
Ownership percentage not fully diluted 6.70%    
ILiAD Biotechnologies LLC [Member]      
Schedule of Equity Method Investments [Line Items]      
Aggregrate investment $ 7,000,000 $ 7,000,000  
Private financing - D units     $ 42,836,000
Invested amount - multi-national pharma     30,000,000
Additional invested amount - D units     $ 1,000,000